Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000594506 | SCV000701585 | uncertain significance | not provided | 2016-10-03 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000594506 | SCV001033801 | likely benign | not provided | 2025-01-27 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004024706 | SCV004915741 | uncertain significance | Inborn genetic diseases | 2022-12-20 | criteria provided, single submitter | clinical testing | The c.2261T>C (p.L754P) alteration is located in exon 11 (coding exon 10) of the ACAN gene. This alteration results from a T to C substitution at nucleotide position 2261, causing the leucine (L) at amino acid position 754 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |